MIA's research pivotal in TGA's approval of new therapy
1 February 2016
Clinical research undertaken at Melanoma Institute Australia (MIA) has been pivotal in supporting the recent Therapeutic Goods Administration (TGA) approval of Opdivo (nivolumab) for advanced melanoma.
Australians welcome the news that Opdivo has been approved for use to treat advanced melanoma patients as a stand-alone treatment or in combination with Yervoy (ipilimumab). The combination of Opdivo and Yervoy for advanced melanoma is the first approval of its kind in Australia.
Opdivo, which is proven to improve survival, helps the body’s immune system to recognise and attack melanoma cells, which often masquerades as normal cells to avoid detection. Opdivo is a checkpoint inhibitor that blocks an immune-suppressing protein called PD-1. MIA, working with other leading melanoma researchers around the world, published two key studies that contributed to the approval of Opdivo by the TGA.
In one study, the research found that Opdivo improves overall survival among previously untreated patients who have advanced melanoma without a BRAF mutation.
The other study found that among previously untreated patients with metastatic melanoma, Opdivo alone or combined with Yervoy resulted in significantly longer survival than with Yervoy alone.
MIA’s Associate Professor Georgina Long, a lead research investigator for the studies, said: “It is great news to add another drug (an anti-PD-1 immunotherapy) to the armamentarium against melanoma; the next step is for consideration by the PBS for funding.”
A must-read personal account by Garry Maddox in The Sydney Morning Herald of how immunotherapy is revolutionising melanoma treatment.
On Friday, a publication that lays out the steps needed to find out if a systematic screening program for melanoma would benefit all Australians was published in the Australia & New Zealand Journal of Public Health.
Melanoma March events have been cancelled. A Virtual March will be held on Sunday 29th March. Read this statement from MIA CEO Matthew Browne.
Thank you to the thousands of Aussies who bought ‘Game On Mole‘ t-shirts, took selfies, shared t-shirt pics on social media and started lifesaving conversations around sun safety and skin health.
Melanoma patients now have greater access to subsidised immunotherapy thanks to additional treatments today being listed on the PBS.
Brisbane couple Leon and Tamra Betts were, like thousands of others around Australia, on the couch watching MAFS when newlywed Natasha ran through her weekly beauty routine. When they heard the 26-year-old mention solarium use, they were shocked, and then saddened, prompting this open letter to all young Australians.
Professor Richard Scolyer, Co-Medical Director of Melanoma Institute Australia, will welcome international attendees this weekend to a sold-out, two-day course on ‘Pigmented Lesions and Other Hot Topics in Dermatopathology’.
It is time for a reality check on solariums.
They have no place in anyone’s beauty routine.
Throughout January our community created, hosted and participated in some amazing events, each of them helping us on our quest to reach zero deaths from melanoma.
Australian television presenter, interior designer and mother Kyly Clarke has been announced as the new Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign Melanoma March.
Melanoma Institute Australia has recently partnered with three other organisations to boost support for melanoma patients and their carers across Australia.
Melanoma patients and their families across Western Australia will benefit from strengthened and expanded services with the merging of melanomaWA and Melanoma Institute Australia.
Australian researchers have played a critical role in the discovery of a potential new test to predict which early stage melanoma patients are at high risk of their disease recurring and progressing.
We are extremely grateful for our community fundraisers, who, even in this difficult time, have given up their time and effort to fundraise so we can continue to work towards our goal of zero deaths from melanoma.
Melanoma patients are set to benefit from subsidised access to immunotherapy treatment for high risk early-stage and advanced-stage melanoma patients.
An informative article on how immunotherapy is revolutionising cancer treatment, written by Jill Margo and featured in the Australian Financial Review.
Melanoma patients and their families in the Riverina will benefit from strengthened and sustained melanoma services with the merger of the Amie St Clair Melanoma Trust and Melanoma Institute Australia.
Belmont High School at Lake Macquarie has been announced winner of the 2019 SunSafe Student Ambassador Program video competition.
It’s time again to say thank you to our amazing community fundraisers!
Videos of the sessions at the recent Patient Information Evening co-hosted by Melanoma Institute Australia (MIA) and Melanoma Patients Australia (MPA) are now available for viewing.